Phase 3 Leukaemia Trial, Recruiting NCT06853951 Sponsor: Ain Shams University Condition: Leukaemia
Back to Leukaemia

Phase 3 Leukaemia Trial, Recruiting

NCT06853951
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The legal representative of the potential participant (such as a parent or guardian) must be willing to give formal written consent for participation in the study.
  • The participant must be able to swallow and take medication by mouth.
  • The participant must be between 2 and 18 years old at the time of diagnosis.

Who may not be able to join:

  • People who have a documented allergic reaction to the type of heart-protective medications used in this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Manal Hamed El-Hamamsy, Prof, Ain Shams University

Phone: +201093942389

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
18 July 2023
Est. completion
30 March 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change in Left Ventricular Ejection Fraction (LVEF)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov